Project Grant R42AG058333

Summary Tauvision, Inc. received a $986,768 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective September 20, 2025 through September 19, 2026. The company is developing an eyedrop-based diagnostic test to detect Alzheimer's disease biomarkers through a non-invasive imaging approach. The project addresses a critical clinical need by offering an alternative to current positron emission tomography (PET) scanning, which is expensive...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...

This $427,625 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the University of Washington aims to develop and optimize two novel blood-based biomarker assays to improve clinical diagnosis and differential diagnosis of Parkinson's disease (PD) and multiple system atrophy (MSA). The key products and services to be delivered under this 2-year grant include: Further development and optimization of a flow cytometry-based assay (APOGEE) to directly quantify...

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...

This Project Grant award of $320,000 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) is supporting research at the University of Texas Medical Branch at Galveston (UTMB) to investigate the impact of pathological tau protein on alternative polyadenylation (APA) regulation in Alzheimer's disease. The study aims to comprehensively profile APA transcripts and gene expression in mouse primary hippocampal neurons expressing wild-type and mutant tau proteins....

Federal Grant Award Summary Award Details: The National Institute on Aging (Aging Research program, CFDA 93.866) awarded Adeptrix Corp a Project Grant of $499,940 on September 11, 2025, with an ultimate completion date of August 31, 2026. The award supports research and development conducted in Massachusetts. Products and Services: Adeptrix is developing TAUTRACE, an ultrasensitive immunoassay platform designed to detect and quantify phosphorylated tau (pTau) biomarkers in cerebrospinal fluid...

The National Institute on Aging (NIA) awarded a $459,250 Project Grant (CFDA 93.866 - Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate and validate the use of dried blood spot (DBS) samples for measuring Alzheimer's disease (AD) biomarkers. The key objectives are to: 1) optimize fingerstick collection methods and validate assays for three key AD biomarkers (pTau217, GFAP, and NFL) in DBS samples; 2) establish if DBS...

Federal Project Grant Award Summary Redwood Neuro Inc. received a $506,061 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded on September 15, 2025, with a completion date of August 31, 2026. The awardee will develop and validate the SimoLISA platform, an ultra-sensitive, cost-effective immunoassay technology designed to democratize early detection and longitudinal monitoring of Alzheimer's disease (AD). The platform employs a proprietary...

Award Summary Oligomerix Inc. received a $2.49M Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) on August 20, 2025, to conduct preclinical toxicology studies supporting the clinical development of OLX-07010, a small molecule drug candidate for Alzheimer's disease. The primary deliverable is a 13-week Good Laboratory Practice (GLP) oral gavage toxicity study in Beagle dogs with a 4-week recovery period, designed to de-risk a planned...

This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), aims to investigate the presence of Alzheimer's disease (AD) biomarkers in nasally exhaled breath. The $440,000 award to Northwestern University will fund research to test the hypothesis that neural proteins associated with AD, such as tau and beta-amyloid, can be detected and quantified in nasally exhaled breath samples. The 2-year project period runs from...